Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus (NYSE:TEVA).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEVA, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 23 uncommon options trades for Teva Pharmaceutical Indus.
This isn't normal.
The overall sentiment of these big-money traders is split between 56% bullish and 39%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $70,004, and 21 are calls, for a total amount of $2,214,293.
Expected Price Movements
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $5.0 to $25.0 for Teva Pharmaceutical Indus over the recent three months.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 5254.92 with a total volume of 189,085.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Teva Pharmaceutical Indus's big money trades within a strike price range of $5.0 to $25.0 over the last 30 days.
Teva Pharmaceutical Indus Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TEVA | CALL | TRADE | BULLISH | 10/17/25 | $0.32 | $0.27 | $0.31 | $21.00 | $838.6K | 37.6K | 35.0K |
| TEVA | CALL | TRADE | BULLISH | 01/15/27 | $3.8 | $3.65 | $3.75 | $20.00 | $187.5K | 8.1K | 508 |
| TEVA | CALL | SWEEP | BEARISH | 10/17/25 | $0.37 | $0.35 | $0.35 | $21.00 | $141.6K | 37.6K | 4.0K |
| TEVA | CALL | SWEEP | BEARISH | 10/17/25 | $0.31 | $0.29 | $0.31 | $21.00 | $121.3K | 37.6K | 7.9K |
| TEVA | CALL | TRADE | BEARISH | 01/15/27 | $4.1 | $3.85 | $3.85 | $20.00 | $107.8K | 8.1K | 838 |
About Teva Pharmaceutical Indus
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
After a thorough review of the options trading surrounding Teva Pharmaceutical Indus, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Teva Pharmaceutical Indus's Current Market Status
- Currently trading with a volume of 15,129,348, the TEVA's price is up by 0.99%, now at $19.37.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 36 days.
Professional Analyst Ratings for Teva Pharmaceutical Indus
In the last month, 1 experts released ratings on this stock with an average target price of $26.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Teva Pharmaceutical Indus with a target price of $26.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Teva Pharmaceutical Indus with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
